中慧生物(2627.HK)孖展暂超购逾1793倍

Core Insights - 中慧生物-B (2627.HK) is set to close its public offering tomorrow, with brokers having lent at least 93.052 billion HKD in margin financing, resulting in an oversubscription of over 1,793 times compared to the public offering amount of 51.84 million HKD [1] - The company aims to raise a maximum of 518 million HKD and is scheduled to list on Friday, October 8, with CITIC Securities and China Merchants Bank International as sponsors [1] - 中慧生物 has two core products: a quadrivalent influenza virus subunit vaccine and an in-development freeze-dried human rabies vaccine [1] - The company's loss for the first quarter of this year has widened to 87.3 million RMB year-on-year [1]